How to Get Tresiba in Rhode Island

What Is Tresiba and Why Physicians Prescribe It

Insulin degludec is an ultra-long-acting basal insulin with a half-life of approximately 25 hours, producing a duration of action exceeding 42 hours at steady state. That extended profile supports flexible dosing windows of 8 to 40 hours between injections without clinically meaningful loss of glycemic control. The FDA approved Tresiba for adults with type 1 and type 2 diabetes in September 2015 and expanded the label to include children as young as 1 year in 2017. [1]

The DEVOTE trial (N=7,637) compared insulin degludec 100 U/mL to insulin glargine 100 U/mL over a median follow-up of 2.0 years in adults with type 2 diabetes at high cardiovascular risk. Rates of major adverse cardiovascular events (MACE) were 8.5% with degludec versus 9.3% with glargine, confirming non-inferiority (hazard ratio 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority). [2] Severe hypoglycemia occurred in 4.9% of degludec-treated patients versus 6.6% on glargine (rate ratio 0.60; P<0.001). [2]

The American Diabetes Association 2024 Standards of Care classify basal insulin analogs as preferred over NPH for lower nocturnal hypoglycemia risk and state that "insulin degludec may be considered when further reduction of hypoglycemia risk is a clinical priority." [3] Rhode Island physicians cite that guideline language most often when choosing degludec over biosimilar glargines for patients with recurrent overnight lows or erratic schedules.

Tresiba is available in two concentrations: U-100 (FlexTouch pen) and U-200 (FlexTouch pen). The U-200 formulation delivers the same number of units in half the injection volume, which many Rhode Island endocrinologists prefer for patients requiring doses above 60 units per day. [1]

Rhode Island Legal Framework for Prescribing and Dispensing Tresiba

Rhode Island law permits any practitioner holding a valid RI DEA-equivalent prescribing license to write for insulin degludec. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), each within their respective scope of practice under RIGL Title 5. [4] There is no state-specific insulin prescribing restriction beyond the practitioner's licensure status.

Telehealth prescribing is explicitly authorized in Rhode Island under the Rhode Island Telehealth Act (RIGL § 27-81-1 et seq.), which requires audio-visual real-time communication for a new prescribing relationship involving controlled substances. Insulin is not a controlled substance, so audio-only encounters may satisfy the prescribing standard under RI law, though most telehealth platforms default to video visits for documentation quality. [4] Prescriptions written via telehealth must meet the same standards as in-person prescriptions: patient identity verified, clinical evaluation documented, and a valid prescriber-patient relationship established.

The Rhode Island Board of Pharmacy licenses 503A compounding pharmacies to prepare and ship patient-specific compounds, but commercially available insulin degludec (Tresiba) is manufactured under an FDA-approved NDA and is not a candidate for 503A compounding under federal law. [5] Rhode Island patients can use licensed mail-order pharmacies, retail chains, or specialty pharmacies for the FDA-approved product. The FDA's drug shortage database shows no current national shortage of insulin degludec as of mid-2025. [5]

Step-by-Step: Getting a Tresiba Prescription in Rhode Island

Step 1. Choose your prescriber pathway. In-person options include endocrinologists, primary care physicians, or certified diabetes care and education specialists (CDCES) across RI health systems such as Lifespan, Care New England, and South County Health. Telehealth options include HealthRX-affiliated clinicians licensed in Rhode Island who can evaluate and prescribe during a video visit, typically within 24 to 72 hours of scheduling.

Step 2. Gather baseline labs. Before your appointment, obtain a current HbA1c (drawn within 90 days), a fasting glucose, a basic metabolic panel (sodium, potassium, creatinine, eGFR), and a complete medication list. Some insurers require documented HbA1c above 8.0% to approve Tresiba over a biosimilar glargine. [3] If you have type 1 diabetes, a C-peptide level drawn during a euglycemic state helps document the diagnosis in PA submissions.

Step 3. Attend your clinical visit. During the visit, the clinician reviews your glycemic data, current insulin regimen, hypoglycemia history, and any comorbidities. Dose calculation starts at 10 units once daily for type 2 diabetes, or as a unit-for-unit conversion from your current basal insulin for type 1 diabetes. [1] The visit typically takes 20 to 45 minutes.

Step 4. Submit the prescription. Prescriptions are sent electronically (e-prescribing) to your preferred Rhode Island pharmacy or mail-order pharmacy. Specify which Tresiba concentration (U-100 or U-200) the clinician intends; the two concentrations are not interchangeable by unit volume and pharmacy substitution errors have been reported to the FDA MedWatch system. [6]

Step 5. Manage prior authorization. Most commercial plans and Rhode Island Medicaid require PA. Collect the prescriber's NPI, the ICD-10 code (E10.65 for type 1 with hyperglycemia; E11.649 for type 2 with unspecified complication), documentation of prior basal insulin trials, and the most recent HbA1c. Turnaround is 3 to 5 business days for standard PA and 24 hours for urgent medical necessity. [4]

Step 6. Receive your medication. Retail Rhode Island pharmacies generally fill in 1 to 2 days. Mail-order delivery adds 2 to 5 business days. Tresiba must be stored refrigerated (36°F to 46°F) before first use; after opening, it can be stored at room temperature (below 86°F) for up to 56 days. [1]

Prior Authorization Requirements for Rhode Island Medicaid

Rhode Island Medicaid (Neighborhood Health Plan RI, UnitedHealthcare Community Plan RI, Tufts Health Unify) covers insulin degludec on the preferred drug list with prior authorization for both type 1 and type 2 diabetes. The typical PA criteria include:

• Documented diagnosis of type 1 or type 2 diabetes with ICD-10 coding
• HbA1c above 7.5% (or above 8.0% for some plans) within the past 90 days
• Trial of at least one formulary basal insulin (usually insulin glargine biosimilar) unless contraindicated or clinically inappropriate
• Documented rationale for degludec: recurrent severe or nocturnal hypoglycemia, variable schedule, or documented inadequate glycemic control on glargine [3]
• Prescriber attestation of medical necessity

The ADA's 2024 Standards of Care note that "hypoglycemia, particularly severe hypoglycemia, is a major barrier to achieving glycemic goals and should be proactively addressed." [3] That language supports medical-necessity arguments when glargine trials have produced unacceptable hypoglycemia.

Rhode Island Medicaid PA forms are submitted through the Pharmacy Benefits Management portal or by phone (Gainwell Technologies administers RI Medicaid pharmacy benefits). Denials can be appealed; approximately 40 to 60% of initial PA denials for basal insulin analogs are overturned on first-level appeal when clinical documentation is complete. [7]

Telehealth Providers in Rhode Island Prescribing Tresiba

The table below outlines the clinical decision framework HealthRX clinicians use when evaluating a Rhode Island patient for insulin degludec via telehealth. Each criterion maps to a PA documentation category.

| Clinical Factor | Favors Degludec | Documentation for PA | |---|---|---| | Nocturnal hypoglycemia (BG <70 mg/dL overnight) | Yes | CGM download or glucose log | | Highly variable daily schedule | Yes | Patient attestation, shift-work record | | HbA1c above 8.0% on glargine | Yes | Lab report within 90 days | | Dose above 60 units/day | Yes (U-200 option) | Prescription history | | Pregnancy or planning pregnancy | No (use NPH or glargine per ACOG) | N/A |

Telehealth platforms serving Rhode Island patients typically require: a valid government-issued ID, a current medication list, the most recent HbA1c result, and either CGM data (Dexterity Clarity, LibreView) or a 2-week glucose log. The visit is billed under CPT 99213 or 99214 for established patients and 99203 or 99204 for new patients, consistent with CMS E/M guidelines effective January 2021. [8]

After the visit, the prescriber sends an e-prescription to the patient's preferred pharmacy. If the patient's insurer requires PA, the telehealth clinician's office handles the submission. HealthRX Rhode Island patients have received Tresiba coverage approval within 72 hours in 80% of cases when the PA submission includes CGM data showing at least one nocturnal hypoglycemic episode below 54 mg/dL. [9]

Cost, Insurance, and Patient Assistance in Rhode Island

Without insurance, a 5-pack of Tresiba FlexTouch U-100 (3 mL each, 300 units per pen) lists at approximately $530 to $580 at Rhode Island retail pharmacies as of mid-2025. The Novo Nordisk Patient Assistance Program (NovoCare) provides Tresiba at no cost to uninsured patients with household income at or below 400% of the federal poverty level. [10]

Novo Nordisk's My$99Insulin program caps out-of-pocket cost at $99 per month for any Novo Nordisk insulin, including Tresiba, for commercially insured patients who are not covered by government programs. [10] Rhode Island residents enrolled in Medicaid or Medicare Part D are not eligible for the manufacturer coupon but may access the Extra Help (Low Income Subsidy) program through SSA, which typically reduces Part D insulin copays to $35 per month or less under the Inflation Reduction Act insulin cap effective January 2023. [11]

GoodRx prices for Tresiba at major Rhode Island chains (CVS, Walgreens, Rite Aid, Stop and Shop Pharmacy) range from $420 to $510 per 5-pack depending on the specific store and promotion. GoodRx discounts are not usable concurrently with insurance but can bridge a gap while PA is pending.

Transferring an Existing Tresiba Prescription to Rhode Island

Rhode Island pharmacy law (RIGL § 5-19.1) permits transfer of a valid prescription between licensed pharmacies across state lines for non-controlled medications. Insulin degludec is a non-controlled Schedule V or lower substance, so transfer is straightforward. The receiving Rhode Island pharmacy contacts the originating pharmacy directly to confirm remaining refills and prescriber information.

Patients moving to Rhode Island with an active Tresiba prescription written by an out-of-state physician should note that the original prescriber must be licensed in the state where the prescription was written, not in Rhode Island. The prescription remains valid for 12 months from the date of issuance under most state laws, after which a Rhode Island-licensed prescriber must issue a new prescription. [4]

If your out-of-state endocrinologist continues to treat you via telehealth, they must hold either a Rhode Island medical license or a valid Interstate Medical Licensure Compact (IMLC) authorization. As of 2025, Rhode Island participates in IMLC. [4] Prescriptions written by a compact-licensed provider for Rhode Island-based patients are valid at any RI pharmacy.

Labs Needed Before Starting Tresiba

Clinical guidelines from the ADA and the Endocrine Society recommend establishing baseline laboratory values before initiating or switching to any basal insulin. [3] The minimum lab panel before Tresiba in Rhode Island includes:

HbA1c. Drawn within 90 days. Establishes glycemic baseline and satisfies most PA criteria. The ADA defines target HbA1c as below 7.0% for most non-pregnant adults, with individualized targets for elderly or high-risk patients. [3]

Fasting glucose. Drawn the morning of the appointment. Allows same-day dosing calculation.

Basic metabolic panel. Creatinine and eGFR guide dose adjustments; insulin degludec clearance is not renally mediated, but renal impairment increases hypoglycemia risk. [1] Potassium is checked because insulin shifts potassium intracellularly; hypokalemia below 3.5 mEq/L warrants correction before initiating insulin. [1]

Thyroid function (optional but recommended for type 1 diabetes). TSH every 1 to 2 years per ADA guidelines; an out-of-range TSH at baseline prevents erroneous attribution of glycemic instability to the new insulin. [3]

Lipid panel (if not drawn in the past 12 months). Not required for PA but supports comprehensive metabolic risk documentation. [3]

A continuous glucose monitor (CGM) download covering 14 days or more provides time-in-range data (target above 70%), percentage below 70 mg/dL (target below 4%), and coefficient of variation. CGM data are more compelling than HbA1c alone when documenting hypoglycemia frequency for a PA submission. [9]

Dosing, Titration, and Monitoring After Starting Tresiba

Starting doses follow the FDA-approved label. For insulin-naive type 2 diabetes patients, the recommended starting dose is 10 units subcutaneously once daily. For patients converting from another basal insulin, the initial Tresiba dose is the same number of units as the previous basal insulin total daily dose. [1] Conversion from twice-daily NPH insulin uses 80% of the total daily NPH dose as the starting degludec dose to reduce hypoglycemia risk during the transition. [1]

Titration follows the "treat-to-target" approach endorsed by the ADA: increase the dose by 2 units every 3 days if fasting glucose averages above 90 to 130 mg/dL (the patient's individualized target range). [3] Dose reductions of 10 to 20% are recommended for any fasting glucose below 70 mg/dL. Full pharmacodynamic steady state with insulin degludec is reached after 2 to 3 days of once-daily dosing, which is faster than the 4 to 5 days reported for some other ultra-long-acting preparations. [12]

Follow-up labs include HbA1c at 3 months after initiation and then every 3 to 6 months depending on stability. [3] A CGM-derived GMI (glucose management indicator) can substitute for HbA1c in patients with hemoglobin variants affecting A1c accuracy. [9]

Injection Technique and Storage for Rhode Island Patients

Tresiba is injected subcutaneously in the abdomen, thigh, or upper arm. Rotation within a single site is preferred over rotating between sites to minimize variability. [1] Do not inject into lipohypertrophic tissue; absorption from lipohypertrophic sites is erratic and can reduce Tresiba's characteristic flat pharmacokinetic profile. [6]

Needles are not included with Tresiba FlexTouch pens and must be purchased separately. Compatible pen needles range from 4 mm to 8 mm; 4 mm 32-gauge needles produce equivalent subcutaneous delivery with less pain than longer gauges and are recommended by the Forum for Injection Technique (FIT). [13]

Storage is straightforward. Unopened pens require refrigeration between 36°F and 46°F until the expiration date. An opened pen stores at room temperature (below 86°F) for 56 days, the longest in-use period of any commercially available basal insulin as of 2025. [1] That 56-day window is particularly useful for Rhode Island patients who travel frequently or lack consistent refrigerator access.

Pediatric Use in Rhode Island

The FDA extended the Tresiba indication to children 1 year and older in June 2017, based on data from the BEGIN YOUNG trial comparing degludec to insulin detemir in 350 children aged 1 to 17 years with type 1 diabetes. [14] HbA1c reductions were comparable (estimated treatment difference 0.15%; 95% CI -0.10 to 0.40), and overall hypoglycemia rates did not differ significantly between arms. [14] Rhode Island pediatric endocrinologists at Hasbro Children's Hospital and Brown Medicine Pediatric Endocrinology follow ADA Pediatric Standards recommending basal insulin analogs over NPH for most pediatric type 1 diabetes patients. [3]

Prescribing for pediatric Rhode Island Medicaid patients requires the same PA criteria as adults, with the additional documentation of the child's weight-based dose and a pediatric endocrinology consult note when available.